Article info
PDFLaboratory science
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study
- Correspondence to Dr Anthony B Daniels, Vanderbilt Eye Institute, 2311 Pierce Avenue, Vanderbilt University Medical Center, Nashville, Tennessee, USA; anthony.b.daniels{at}vumc.org
Citation
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study
Publication history
- Received December 3, 2020
- Revised April 9, 2021
- Accepted April 13, 2021
- First published May 10, 2021.
Online issue publication
January 21, 2022
Article Versions
- Previous version (21 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.